Novillo Villajos, ApoloniaRomero Lorca, AliciaGaibar Alonso, MaríaRubio Alonso, MargaritaFernández Santander, Ana2016-10-132016-10-132017Novillo, A., Romero-Lorca, A., Gaibar, M., Rubio, M., & Fernández-Santander, A. (2017). Tamoxifen metabolism in breast cancer treatment: Taking the focus off the CYP2D6 gene. The Pharmacogenomics Journal, 17(2), 109-111. DOI: 10.1038/tpj.2016.731470269X14731150http://hdl.handle.net/11268/5867Tamoxifen (TAM) has been widely used to treat estrogen receptor (ER)-positive breast cancer, and has led to reduction of 50% in the annual recurrence rate and 30% in breast cancer mortality after 5 years of treatment.1 The prodrug TAM is a selective ER modulator that antagonizes ERs in cancer cells. However, compared with its two active metabolites 4-hydroxy-TAM (4-OH-TAM) and endoxifen, it is a relatively weak antiestrogen.engjournal article10.1038/tpj.2016.73restricted accessTamoxifenoMamas - CáncerCáncer